These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 24229757)

  • 21. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.
    Breil F; Verstuyft C; Orostegui L; Buhl C; Alvarez JC; Chouinard G; Becquemont L; Corruble E
    Int J Neuropsychopharmacol; 2008 Aug; 11(5):727-8. PubMed ID: 18384706
    [No Abstract]   [Full Text] [Related]  

  • 22. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.
    Fukuda T; Nishida Y; Imaoka S; Hiroi T; Naohara M; Funae Y; Azuma J
    Arch Biochem Biophys; 2000 Aug; 380(2):303-8. PubMed ID: 10933885
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
    de Leon J
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):532-4. PubMed ID: 26088654
    [No Abstract]   [Full Text] [Related]  

  • 24. Tolerance to desvenlafaxine in rapid metabolizing depressed patients.
    Parker GB; Brotchie HL; Hyett M
    Int Clin Psychopharmacol; 2011 Mar; 26(2):84-7. PubMed ID: 21119521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A possible bupropion and imipramine interaction.
    Shad MU; Preskorn SH
    J Clin Psychopharmacol; 1997 Apr; 17(2):118-9. PubMed ID: 10950476
    [No Abstract]   [Full Text] [Related]  

  • 26. Novel CYP2D6 and CYP2C19 variants identified in a patient with adverse reactions towards venlafaxine monotherapy and dual therapy with nortriptyline and fluoxetine.
    Chua EW; Foulds J; Miller AL; Kennedy MA
    Pharmacogenet Genomics; 2013 Sep; 23(9):494-7. PubMed ID: 23799451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients.
    Otani K; Tybring G; Mihara K; Yasui N; Kaneko S; Ohkubo T; Nagasaki T; Sugawara K
    Eur J Clin Pharmacol; 1998 Jan; 53(5):347-9. PubMed ID: 9516035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
    Arneth B; Shams M; Hiemke C; Härtter S
    Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.
    Berm E; Kok R; Hak E; Wilffert B
    Pharmacopsychiatry; 2016 Sep; 49(5):186-190. PubMed ID: 27101231
    [No Abstract]   [Full Text] [Related]  

  • 31. A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication.
    Lee SY; Ki CS; Hong KS; Kim JW
    J Korean Med Sci; 2004 Oct; 19(5):750-2. PubMed ID: 15483356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
    Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
    OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant CYP2D6 metabolizer phenotypes do not show increased frequency in patients undergoing ECT after antidepressant therapy.
    Mirzakhani H; van Dormolen J; van der Weide K; Guchelaar HJ; van Noorden MS; Swen J
    Pharmacogenet Genomics; 2015 Oct; 25(10):515-7. PubMed ID: 26230381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of patients using drugs metabolized by cytochrome P450 2D6 in different populations: a cross-sectional study.
    Mulder H; Heerdink ER; van Iersel EE; Wilmink FW; Egberts AC
    Ann Pharmacother; 2007 Mar; 41(3):408-13. PubMed ID: 17341534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
    Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
    Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?
    Macaluso M; Preskorn SH
    J Clin Psychopharmacol; 2011 Apr; 31(2):143-5. PubMed ID: 21346604
    [No Abstract]   [Full Text] [Related]  

  • 38. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
    Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
    Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics.
    Shen HW; Wu C; Jiang XL; Yu AM
    Biochem Pharmacol; 2010 Jul; 80(1):122-8. PubMed ID: 20206139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytochrome P450 2D6 polymorphism and character traits.
    Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
    Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.